Method of detecting intrusion based on improved support vector machine
    183.
    发明授权
    Method of detecting intrusion based on improved support vector machine 有权
    基于改进支持向量机的入侵检测方法

    公开(公告)号:US09298913B2

    公开(公告)日:2016-03-29

    申请号:US14201939

    申请日:2014-03-10

    Abstract: A method of detecting network intrusion based on improved support vector machine is disclosed. The method comprises the steps of identifying a plurality of features; computing information gain of each of the features; selecting a pre-determined number of features based on the computed information gain and augmenting that set of pre-determined number of features with special features to form a set of selected features; and classifying a network connection based on the selected features using support vector machine. In order to achieve better detection accuracy, cross-validation and grid-search are applied to select the radial basis function for the support vector machine.

    Abstract translation: 公开了一种基于改进的支持向量机检测网络入侵的方法。 该方法包括识别多个特征的步骤; 计算每个特征的信息增益; 基于所计算的信息增益来选择预定数量的特征,并且增加具有特殊特征的预定数量的特征的集合以形成所选特征的集合; 并使用支持向量机根据所选择的特征对网络连接进行分类。 为了实现更好的检测精度,应用交叉验证和网格搜索来选择支持向量机的径向基函数。

    Method of Providing Mobility Support to Internet Protocol Version 6 (IPv6) using Filtering Technology
    184.
    发明申请
    Method of Providing Mobility Support to Internet Protocol Version 6 (IPv6) using Filtering Technology 审中-公开
    使用过滤技术为互联网协议版本6(IPv6)提供移动性支持的方法

    公开(公告)号:US20150146746A1

    公开(公告)日:2015-05-28

    申请号:US14201947

    申请日:2014-03-10

    Inventor: Chak Fong CHEANG

    CPC classification number: H04W8/085 H04L69/161 H04W80/045

    Abstract: A method of providing mobility support to Internet Protocol version 6 (IPv6) using filtering technology is disclosed. The method comprises the steps of: providing a filter layer below the internet layer and above the network access layer in the TCP/IP stack; and modifying the packets using the filter layer. The step of modifying packets further comprises the steps of detecting the movement of a mobile node, and updating the movement of the mobile node to other nodes. The step of detecting the movement of the mobile node further comprises a step of replacing the prefix in the receiving packets before passing the receiving packets to the non-mobility-capable IPv6 module of the internet layer for hiding the movement of the mobile node; The step of modifying the packets also comprises the steps of adding extension headers to the packets, deleting extension headers from the packets and replacing IP addresses of the packets for the survivability of the ongoing connections.

    Abstract translation: 公开了一种使用过滤技术为互联网协议版本6(IPv6)提供移动性支持的方法。 该方法包括以下步骤:在互联网层之下和TCP / IP栈中的网络接入层之上提供一个过滤层; 并使用过滤层修改数据包。 修改分组的步骤还包括检测移动节点的移动以及更新移动节点到其他节点的移动的步骤。 检测移动节点的移动的步骤还包括在将接收分组传递到互联网层的不具有移动能力的IPv6模块之前,将接收分组中的前缀替换为隐藏移动节点的移动的步骤; 修改分组的步骤还包括以下步骤:将扩展头添加到分组,从分组中删除扩展头,并替换分组的IP地址以获得正在进行的连接的生存性。

    Novel autophagy enhancer for treatment of neurodegenerative diseases
    186.
    发明申请
    Novel autophagy enhancer for treatment of neurodegenerative diseases 有权
    用于治疗神经变性疾病的新型自噬增强剂

    公开(公告)号:US20150050363A1

    公开(公告)日:2015-02-19

    申请号:US14231671

    申请日:2014-03-31

    CPC classification number: A61K36/69 A61K31/704

    Abstract: Use and application of Onjisaponin B derived and isolated from Radix Polygalae as novel autophagy enhancer are provided. A method of preventing, treating and/or delaying the onset of neurodegenerative diseases comprising administering an effective amount of Onjisaponin B is also provided.

    Abstract translation: 本发明提供了从根部提取和分离的Onjisaponin B作为新的自噬增强剂的应用和应用。 还提供了预防,治疗和/或延缓神经变性疾病发作的方法,包括给予有效量的Onjisaponin B.

    NOVEL TREATMENT OF GEFITINIB-RESISTANT NON-SMALL-CELL LUNG CANCER
    187.
    发明申请
    NOVEL TREATMENT OF GEFITINIB-RESISTANT NON-SMALL-CELL LUNG CANCER 审中-公开
    耐药性非小细胞肺癌的新疗法

    公开(公告)号:US20140371254A1

    公开(公告)日:2014-12-18

    申请号:US14285651

    申请日:2014-05-23

    CPC classification number: A61K31/4741

    Abstract: The present invention discloses a method of preventing and treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

    Abstract translation: 本发明公开了一种预防和治疗吉非替尼抗性非小细胞肺癌的方法,包括给予有效量的生物碱。 还公开了包含与用于治疗吉非替尼非小细胞肺癌的药物载体混合的生物碱的药物组合物。

    Method and pharmaceutical composition for treating cancer

    公开(公告)号:US11149271B2

    公开(公告)日:2021-10-19

    申请号:US16120606

    申请日:2018-09-04

    Abstract: A method of treating a subject suffering from cancer includes administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule is isolated or derived from a plant of the genus Taxus. A method of inhibiting growth or proliferation of cancer cells includes contacting cancer cells with the RNA molecule; and a pharmaceutical composition for treating cancer includes the RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector include the double-stranded RNA molecule.

    Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use

    公开(公告)号:US10759757B2

    公开(公告)日:2020-09-01

    申请号:US15271368

    申请日:2016-09-21

    Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

Patent Agency Ranking